Scope, Claims, and US Patent Landscape for United States Patent 5,603,918 (ipratropium bromide + albuterol sulfate micronized aerosol with soya lecithin and CFC propellant)
US Patent 5,603,918 centers on a specific metered-dose aerosol formulation combining micronized ipratropium bromide and micronized albuterol sulfate with soya lecithin as a suspending agent, delivered with a three-component CFC propellant mixture. Claim scope is anchored by (i) micronization, (ii) salt identity (bromide and sulfate), (iii) a quantitative lecithin range (0.1 to 0.3 wt% and enumerated sub-values), (iv) CFC propellant composition constraints, and (v) “consists essentially of” language that narrows permissible formulation substitutions.
The practical exclusivity question for US generic entry is not whether ipratropium + albuterol are known, but whether a competing aerosol infringes the combination in the claim’s tight formulation envelope (especially the lecithin concentration basis and the specific propellant mixture).
What is US Patent 5,603,918 scope and what does it claim?
Core claim theme. The patent claims a stable aerosol formulation comprising:
- Micronized salts: ipratropium bromide + albuterol sulfate
- Soya lecithin as suspending agent
- A propellant (explicitly defined in dependent claims as a CFC mixture)
Independent claim 1 is the principal “formulation box”:
- “An aerosol formulation” with effective amount of micronized ipratropium salt and micronized albuterol salt
- effective amount of soya lecithin as suspending agent
- and a propellant
Key dependent claim 2 tightens the propellant:
- mixture of trichloromonofluoromethane + dichlorodifluoromethane + dichlorotetrafluoroethane
Key dependent claim 3 tightens lecithin to a numeric range:
- 0.1 to 0.3 wt% soya lecithin
- the “based on” language is explicit: based on combined weight of (ipratropium salt + albuterol salt + lecithin + propellant)
Claims 4 and 5 lock the salts:
- ipratropium = ipratropium bromide
- albuterol = albuterol sulfate
Claims 6 and 3 effectively repeat the same lecithin quantitative framework.
Claim 7 introduces a second major tightening mechanism:
- “consists essentially of” formulation
- requires “effective amount” of:
- micronized ipratropium bromide
- micronized albuterol sulfate
- micronized soya lecithin as suspending agent (lecithin “effective amount”)
- propellant “consists essentially of” the defined three-CFC mixture
- and hard-wires the lecithin range (0.1 to 0.3 wt%) with the same “based on combined weight” basis
Claims 8 and 9 further narrow to preferred numeric endpoints:
- about 0.1 wt%
- about 0.2 wt%
Claims 10–14 cover a formulation method:
- combining micronized ipratropium salt with micronized albuterol salt, lecithin, and propellant to form a stable aerosol
- and depend on the same salt and propellant/lecithin constraints.
Which components drive infringement risk under claim 1 vs dependent claims 2–9?
Claim 1 infringement hinges on:
- Aerosol formulation (not dry powder; not nebulizer concentrate)
- Micronized ipratropium pharmaceutically acceptable salt
- Micronized albuterol pharmaceutically acceptable salt
- Soya lecithin as suspending agent
- A propellant
Because claim 1 does not, on its face, require the specific propellant mixture or a numeric lecithin range, an accused formulation could still be within claim 1 even with different CFC/HFA blends, unless prosecution history limits “propellant” or “micronized” in practice.
But dependent claims 2–9 create narrower “escape-proof” benchmarks:
- Propellant specificity (claim 2 and claim 7)
- Lecithin numeric range (claim 3 and claim 7)
- Salt identity (claims 4 and 5; and explicit in claim 7)
- Lecithin point values (claims 8–9)
So for infringement mapping, the “tightest” literal targets are:
- the CFC propellant mixture of claim 2 / claim 7, and
- 0.1–0.3 wt% soya lecithin (or “about 0.1” / “about 0.2”) using the stated basis.
How broad is “micronized” and “effective amount” for ipratropium and albuterol?
Micronized. The claims recite micronized salts but do not define particle size. In practice, infringement analysis typically turns on:
- whether the formulation process produces a qualifying micronized fraction, and
- whether the product characterization documents (PSD, sieve analysis, laser diffraction) meet the patent’s micronization threshold.
If a competitor uses submicronization, the term “micronized” likely reads broadly, increasing risk for literal or DOE (doctrine of equivalents) theories, but actual claim construction depends on intrinsic record (not provided).
“Effective amount.” This term is inherently formulation-dependent. An accused product with materially similar API loadings can still land in the claim. However, stability and suspension performance may be argued as functional context if “effective amount” is tied to the patent’s stability objective.
What does the propellant limitation cover, and how does it change legal risk?
Dependent claim 2 is narrow:
- propellant comprises a mixture of:
- trichloromonofluoromethane (CFC-11 class)
- dichlorodifluoromethane (CFC-12 class)
- dichlorotetrafluoroethane (CFC-114 class)
Claim 7 upgrades this with “consists essentially of” for the propellant:
- propellant “consists essentially of” that three-component CFC mixture
Practical consequence.
- Modern inhalation aerosols frequently use non-CFC propellants (HFA blends or other gases). If the competitor uses different propellants, dependent claims 2 and 7 are more likely to avoid literal infringement.
- But claim 1 still includes “a propellant” generally. If “propellant” is interpreted to include the competitor’s gas system, claim 1 remains a potential hook if all other elements (micronized salts + soya lecithin suspending agent) are present.
What formulation differences can avoid the lecithin range and still preserve stability?
Claims 3 and 7 require:
- 0.1 to 0.3 wt% soya lecithin
- with a specific accounting basis: combined weight of ipratropium salt + albuterol salt + lecithin + propellant
Claims 8 and 9 require “about 0.1 wt%” and “about 0.2 wt%.”
Avoidance strategies (legal, not scientific).
- Use lecithin outside the required range (below 0.1 wt% or above 0.3 wt%) to avoid literal infringement of claims 3 and 7.
- Adjust the formulation so that when computed with the claim’s stated basis, the lecithin “wt%” falls outside the range even if total formulation percent by some other basis would appear similar.
- Use a different suspending agent instead of soya lecithin (claim 1 is soya lecithin-specific).
How do the “consists essentially of” phrases narrow substitution?
Claim 7 contains “consists essentially of” for both:
- the formulation components (“wherein the formulation consists essentially of…”), and
- the propellant (“propellant which consists essentially of a mixture of…”).
In US claim interpretation practice, “consists essentially of” permits additional components only if they do not materially affect the basic and novel characteristics of the claimed invention. Here, the “basic and novel characteristics” are strongly framed by:
- micronized dual-salt combination
- soya lecithin suspending agent at defined wt%
- stability with the specified CFC propellant blend.
So a competitor adding excipients is not automatically avoided, but substitutions that materially change stability/suspension behavior, particle settling, or aerosol performance could be argued to exceed the “consists essentially of” boundary.
What does the method-of-formulating claim cover, and how does that impact manufacturing/IP barriers?
Claims 10–14 are composition-adjacent process claims:
- “combining” micronized ipratropium salt with micronized albuterol salt, soya lecithin, and propellant.
Dependence mirrors formulation:
- claim 11: albuterol sulfate
- claim 12: ipratropium bromide
- claim 13: lecithin 0.1–0.3 wt% with same “based on” basis
- claim 14: propellant comprises the defined CFC mixture
Manufacturing risk.
- If a competitor’s final aerosol practice uses the same combination and process steps with the same micronized APIs and lecithin/propellant parameters, method claims can create additional barriers even if the product changes slightly in ways that might be debated under composition claim construction.
- Conversely, if a competitor switches away from the CFC propellant mixture, claim 14 narrows, and the method risk shifts back to claim 10 (general “propellant” and “effective amount”), which can still be argued broadly depending on claim interpretation.
How strong is the patent estate logic given the claim structure?
Even with only the claim text provided, the patent’s internal architecture suggests:
- a broad “anchor” independent claim (claim 1) that can capture varied propellant systems, and
- narrower dependent claims that create numerically and composition-defined targets (lecithin %, salt identities, propellant mixture) suitable for infringement leverage.
From a freedom-to-operate standpoint, the estate is likely most vulnerable to design-arounds at the propellant level and lecithin level, while being harder to avoid if both:
- the APIs are micronized salts of ipratropium bromide and albuterol sulfate, and
- soya lecithin is used as the suspending agent at 0.1–0.3 wt% (or around 0.1–0.2 wt%).
What is the US Orange Book status and FDA regulatory linkage for this patent?
This prompt provides neither:
- the associated drug product name, dosage form, NDA/ANDA/BLA number, nor
- Orange Book listing details that map US Patent 5,603,918 to an FDA application.
Without that linkage, the Orange Book status cannot be determined from the provided data.
What generic entry risks exist for ipratropium + albuterol aerosol combinations?
Key determinant is whether a generic would need to replicate the same formulation envelope.
- If the generic reformulates with non-CFC propellant systems and adjusts lecithin concentration or suspending agent type, the likelihood of literal infringement of claims 2/3/4/5/7/8/9/14 drops materially.
- If the generic preserves micronized dual-salt composition and uses soya lecithin at the required wt% and uses the specified CFC mixture, infringement risk is high across multiple dependent claims.
A second risk layer is “range calculation.”
- Because lecithin wt% is constrained by a defined calculation basis, even small formula changes can alter whether the product falls inside or outside the 0.1–0.3% window.
Which companies are challenging or practicing similar formulations?
No defendant, ANDA filer, licensee, or manufacturing assignee information is included in the prompt. Without those details, identifying specific challengers or practitioners would be unsupported.
How does this patent compare to typical ipratropium/albuterol aerosol formulations?
Typical high-level design space (relevant to the claim boundaries):
- ipratropium: often delivered as ipratropium bromide
- albuterol: often delivered as albuterol sulfate
- suspending agents: often lecithins, polymers, or other surfactant systems
- propellants: historically CFC blends; later HFAs
This patent is distinctive because it couples:
- micronized dual-salt composition
- soya lecithin suspending agent
- a narrow numeric lecithin range
- and, in key dependents, a very specific CFC propellant mixture.
That combination narrows the practical set of infringing products.
Patent landscape mapping: what adjacent patent claim themes likely surround 5,603,918?
Even without additional patent numbers, 5,603,918 sits at the intersection of several common inhalation formulation patent clusters:
1) Combination-product formulation patents
- dual API aerosols (ipratropium + albuterol)
- micronization and suspension stability
2) Suspending agent and surfactant patents
- lecithin types and concentration ranges
- alternatives to soya lecithin
3) Propellant system patents
- CFC to HFA transition reformulations
- propellant blends and droplet/aerosol characteristics
4) Method-of-manufacture / method-of-formulating patents
- combining micronized APIs with suspending agents and propellant
- stability-oriented process steps
For business planning, infringement tends to concentrate on whether the competitor’s formulation reproduces the same “basic and novel characteristics,” especially when “consists essentially of” is present.
Key claim-to-design-around matrix (literal) for US 5,603,918
| Claim element |
Literal requirement in 5,603,918 |
Main design-around lever |
Expected effect |
| Micronized ipratropium salt |
Micronized “pharmaceutically acceptable salt” (claims 4/7 specify bromide) |
Use non-micronized, or micronized different salt form |
May avoid claim 1 (and likely claim 4/7 if salt identity differs) |
| Micronized albuterol salt |
Micronized “pharmaceutically acceptable salt” (claims 5/7 specify sulfate) |
Use different salt form or different particle profile |
Avoid claims 5/7; claim 1 may still read broadly depending on salt acceptance |
| Soya lecithin suspending agent |
“Soya lecithin” in formulation |
Replace lecithin with alternative suspending agent; use no lecithin |
Avoids claims 1/3/7 broadly |
| Lecithin wt% |
0.1 to 0.3 wt% (claims 3/7) on specified basis; “about 0.1/0.2” in claims 8/9 |
Shift outside range or change calculation basis |
Likely defeats claims 3/7/8/9 |
| CFC propellant blend |
Specific 3-component mixture (claims 2/7/14) |
Switch propellant system (HFA or different gases) |
Avoids claims 2/7/14; claim 1 may still be implicated |
| “consists essentially of” |
Narrow component allowance |
Add excipients that materially affect basic characteristics |
Raises non-infringement arguments if “basic characteristics” change |
What about enforcement: would 5,603,918 cover sale of a generic product?
The claims are standard composition and formulation method claims. Enforcement would typically target product infringement:
- If a marketed aerosol meets all limitations of claim 1 (and especially dependent claims),
- and if a competitor uses the same micronized dual-salt system, soya lecithin, and (for dependent targets) the CFC propellant and lecithin range.
Process claims can be asserted against manufacturing steps, but most enforcement pressure focuses on product formulation evidence.
Key Takeaways
- US Patent 5,603,918 is a tightly defined aerosol formulation patent built around micronized ipratropium bromide + micronized albuterol sulfate with soya lecithin as suspending agent.
- Dependent claims add high-precision constraints: soya lecithin at 0.1–0.3 wt% (based on a specific calculation basis) and a specific three-CFC propellant mixture.
- Claim 1 is the broadest hook because it does not require the specific CFC propellant mixture nor the numeric lecithin range, but it is still constrained to soya lecithin and micronized dual-salt composition.
- “consists essentially of” in claim 7 narrows allowable substitutions, strengthening arguments against competitors that change core formulation behavior.
- For design-around planning, the main risk-reduction levers are propellant system changes (to escape claims 2/7/14), lecithin concentration outside the stated range (to escape claims 3/7/8/9), and replacement of soya lecithin (to escape claim 1).
FAQs
1) Does US 5,603,918 require the CFC propellant mixture to infringe claim 1?
Claim 1 requires “a propellant” generally. The specific three-CFC mixture is required only in dependent claim 2 and claim 7 (and claim 14 for method).
2) How is soya lecithin wt% calculated in this patent?
For claims 3 and 7, it is based on the combined weight of the ipratropium salt, the albuterol salt, the soya lecithin, and the propellant.
3) What happens if a formulation uses non-soya lecithin suspending agents?
Replacing soya lecithin is the cleanest literal avoidance lever because soya lecithin is required in claim 1 and carried through the dependent claims.
4) Can “about 0.1 wt%” include values slightly above or below 0.1?
Claim 8 uses “about,” which typically introduces a tolerance. Literal infringement would depend on claim construction and evidence of what range “about” covers.
5) Do the method claims require the same propellant mixture as the composition claims?
Claim 10 is general (“a propellant”), while claim 14 specifies the three-CFC mixture for the method.
References (APA)
No external sources are cited because the prompt provides only the claim text and the patent number, with no drug product linkage, prosecution history, or Orange Book/FDA mapping to support citation.
